Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer
NCT ID: NCT01671891
Last Updated: 2012-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2012-02-29
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rectal cancer with stage II-IV
rectal cancer with stage II-IV intervention: pelvic radiotherapy (45-55Gy) concurrent chemotherapy using capecitabine and oxaliplatin
radiation therapy
45-55Gy
capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)
radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
radiation therapy
45-55Gy
capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)
radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Locally advanced tumor (cT3-4 and/or N+ by transrectal ultrasound and/or pelvic magnetic resonance imaging)
* the distance from anal verge \<= 12cm
* with or without metastasis
* Age 18-75 years old
* ECOG PS 0-2
* No previous chemotherapy or radiotherapy for rectal carcinoma
* Written informed consent
Exclusion Criteria
* rectal cancer with stage I
* distance from verge \>12cm
* age \<=18 or \>=75 years old
* performed previously chemotherapy or radiotherapy
* infection diseases within three months
* serious other diseases
* no written informed consent
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhen Zhang
director of radiotherapy department in Fudan university shanghai cancer center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fudan University Shanghai Cancer Center
Shanghai, China, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wenjie Sun, Master
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
circulating tumor cells in colorectal cancer
Circulating tumors cells as biomarkers: progress toward biomarker qualification
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCRC-NM-1001
Identifier Type: -
Identifier Source: org_study_id